Clementia Pharmaceuticals - CMTA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$26.35
+0 (0.00%)
Get New Clementia Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMTA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Clementia Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $26.35.

This chart shows the closing price for CMTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Clementia Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2019Robert W. BairdDowngradeOutperform ➝ Neutral$27.00Low
2/26/2019Bloom BurtonDowngradeBuy ➝ HoldLow
2/26/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$26.00Medium
2/25/2019WedbushDowngradeOutperform ➝ NeutralLow
1/18/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$24.00Medium
12/16/2018Bloom BurtonReiterated RatingBuyLow
8/15/2018B. RileyLower TargetBuy ➝ Buy$25.00 ➝ $16.00High
8/13/2018Morgan StanleyLower TargetOverweight ➝ Overweight$27.00 ➝ $26.00Low
8/10/2018WedbushReiterated RatingOutperform$26.00Low
3/28/2018B. RileyInitiated CoverageBuy$25.00Medium
11/14/2017WedbushReiterated RatingOutperform$26.00N/A
(Data available from 10/2/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/2/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Clementia Pharmaceuticals logo
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.
Read More

Today's Range

Now: $26.35
Low: $26.28
High: $26.69

50 Day Range

MA: $26.35
Low: $26.35
High: $26.35

52 Week Range

Now: $26.35
Low: $8.10
High: $26.73

Volume

716,706 shs

Average Volume

145,059 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Clementia Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Clementia Pharmaceuticals in the last twelve months:
View the latest analyst ratings for CMTA.

What is the current price target for Clementia Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Clementia Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Clementia Pharmaceuticals in the next year.
View the latest price targets for CMTA.

What is the current consensus analyst rating for Clementia Pharmaceuticals?

Clementia Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CMTA.

What other companies compete with Clementia Pharmaceuticals?

How do I contact Clementia Pharmaceuticals' investor relations team?

Clementia Pharmaceuticals' physical mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company's listed phone number is 514-940-3600 and its investor relations email address is [email protected] The official website for Clementia Pharmaceuticals is www.clementiapharma.com. Learn More about contacing Clementia Pharmaceuticals investor relations.